health canada approval zepbound tirzepatide obesity canada 2024 2025 A 72-week trial compared the two leading GLP-1 medications in adults with (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the 2024: The obesity market's inflection

Nearly half achieved 15% or greater weight loss, approaching surgical outcomes without any operative intervention

Other factors include: Underlying cause of deficiency : Pernicious anaemia, malabsorption disorders, or dietary insufficiency may affect treatment response Medication use : Metformin and proton pump inhibitors can reduce gastrointestinal B12 absorption (though this does not affect the efficacy of intramuscular injections) Individual variation : Differences in how efficiently your body utilises the injected vitamin Adherence to treatment schedule : Missing injections or delaying maintenance doses can slow recovery Discussing these factors with your healthcare provider helps set realistic expectations for your treatment journey

This sensor is based on binding of a spirocyclic SiR ligand to HT, which induces isomerization to the GSH-sensitive and fluorescent zwitterionic form

It enhances glucose balance by targeting the GLP-1, GIP, and glucagon receptors